Prognostic Analysis of 131I Efficacy After Papillary Thyroid Carcinoma Surgery Based on CT Radiomics.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN: 1945-7197 (Electronic) Linking ISSN: 0021972X NLM ISO Abbreviation: J Clin Endocrinol Metab Subsets: MEDLINE
    • Publication Information:
      Publication: 2017- : New York : Oxford University Press
      Original Publication: Springfield, Ill. : Charles C. Thomas
    • Subject Terms:
      Iodine Radioisotopes*/therapeutic use ; Thyroid Neoplasms*/surgery ; Thyroid Neoplasms*/diagnostic imaging ; Thyroid Neoplasms*/radiotherapy ; Thyroid Neoplasms*/pathology ; Tomography, X-Ray Computed*/methods ; Thyroidectomy*/methods ; Thyroid Cancer, Papillary*/surgery ; Thyroid Cancer, Papillary*/diagnostic imaging ; Thyroid Cancer, Papillary*/therapy; Humans ; Male ; Female ; Middle Aged ; Adult ; Prognosis ; Treatment Outcome ; Retrospective Studies ; Young Adult ; Aged ; Adolescent ; Radiomics
    • Abstract:
      Objective: To develop and validate a radiomics-clinical combined model combining preoperative computed tomography (CT) and clinical data from patients with papillary thyroid carcinoma (PTC) to predict the efficacy of initial postoperative 131I treatment.
      Methods: A total of 181 patients with PTC who received total thyroidectomy and initial 131I treatment were divided into training and testing sets (7:3 ratio). Univariate analysis and multivariate logistic regression were used to screen clinical factors affecting the therapeutic response to 131I treatment and construct a clinical model. Radiomics features extracted from preoperative CT images of PTCs were dimensionally reduced through recursive feature elimination and least absolute shrinkage and selection operator. Logistic regression was used to establish a radiomics model, and a radiomics-clinical combined model was developed by integrating the clinical model. The area under the curve (AUC), sensitivity, and specificity were used to evaluate the prediction performance of each model.
      Results: Multivariate analysis revealed that pre-131I treatment serum thyroglobulin was an independent clinical risk factor affecting the efficacy of initial 131I treatment (P = .002), and the AUC, sensitivity, and specificity for predicting the efficacy of initial 131I treatment were 0.895, 0.899, and 0.816, respectively. After dimensionality reduction, 14 key CT radiomics features of PTCs were included. The established radiomics model predicted the efficacy of 131I treatment in the training and testing sets with AUCs of 0.825 and 0.809, sensitivities of 0.828 and 0.636, and specificities of 0.745 and 0.944, respectively. The combined model improved the AUC, sensitivity, and specificity in both sets.
      Conclusion: The preoperative CT-based radiomics model can effectively predict the efficacy of initial postoperative 131I treatment in patients with intermediate- or high-risk PTC, and the radiomics-clinical combined model exhibits better predictive performance.
      (© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.)
    • Comments:
      Erratum in: J Clin Endocrinol Metab. 2024 Dec 18;110(1):e201. doi: 10.1210/clinem/dgae756. (PMID: 39485825)
    • References:
      Cancers (Basel). 2022 Aug 04;14(15):. (PMID: 35954463)
      Front Endocrinol (Lausanne). 2022 Oct 14;13:1015798. (PMID: 36313750)
      J Thyroid Res. 2014;2014:610273. (PMID: 24987542)
      J Surg Oncol. 2020 Oct;122(5):906-913. (PMID: 32588461)
      ScientificWorldJournal. 2013;2013:957680. (PMID: 23533368)
      Ann Nucl Med. 2019 Mar;33(3):177-183. (PMID: 30515649)
      Eur J Endocrinol. 2016 Aug;175(2):R51-64. (PMID: 27257145)
      Thyroid. 2016 Nov;26(11):1623-1629. (PMID: 27549175)
      Diagnostics (Basel). 2023 May 13;13(10):. (PMID: 37238217)
      Clin Exp Med. 2021 May;21(2):277-286. (PMID: 33386568)
      Clin Endocrinol (Oxf). 2019 Sep;91(3):449-455. (PMID: 31102417)
      Front Oncol. 2018 Dec 20;8:640. (PMID: 30619772)
      J Surg Res. 2015 Feb;193(2):731-7. (PMID: 25193578)
      Cancers (Basel). 2023 Apr 27;15(9):. (PMID: 37173976)
      Cancers (Basel). 2023 May 30;15(11):. (PMID: 37296937)
      Eur Arch Otorhinolaryngol. 2017 Feb;274(2):655-660. (PMID: 27225282)
      Endocr Relat Cancer. 2023 Jun 02;30(7):. (PMID: 37043372)
      Clin Nucl Med. 2011 Dec;36(12):1102-5. (PMID: 22064080)
      Eur J Endocrinol. 2014 Aug;171(2):247-52. (PMID: 24866576)
      J Clin Endocrinol Metab. 2023 Oct 18;108(11):e1413-e1423. (PMID: 37167097)
      Endocrine. 2023 Jun;80(3):606-611. (PMID: 36988853)
      Oncol Lett. 2023 Oct 13;26(6):514. (PMID: 37927413)
      Chin Med J (Engl). 2015 Apr 20;128(8):1058-64. (PMID: 25881600)
      Front Endocrinol (Lausanne). 2023 Mar 21;14:1094339. (PMID: 37025409)
      Thyroid Res. 2010 Nov 01;3(1):9. (PMID: 21040579)
      J Clin Med. 2020 Feb 21;9(2):. (PMID: 32098039)
      AJR Am J Roentgenol. 1998 Mar;170(3):747-52. (PMID: 9490968)
      Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):673-80. (PMID: 21210115)
      Thyroid. 2016 Jan;26(1):1-133. (PMID: 26462967)
      J Korean Med Sci. 2015 Jul;30(7):876-81. (PMID: 26130949)
      Thyroid. 2014 May;24(5):872-7. (PMID: 24295076)
    • Grant Information:
      2021RC024 Zhejiang Provincial Medical and Health Technology Project
    • Contributed Indexing:
      Keywords: Iodine-131; papillary thyroid carcinoma; predictive model; radiomics; treatment outcome
    • Accession Number:
      0 (Iodine Radioisotopes)
      0 (Iodine-131)
    • Publication Date:
      Date Created: 20240527 Date Completed: 20241117 Latest Revision: 20241217
    • Publication Date:
      20241218
    • Accession Number:
      PMC11570395
    • Accession Number:
      10.1210/clinem/dgae364
    • Accession Number:
      38801437